Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis

Implications for Diagnostic Imaging of High-Grade Gliomas

Research output: Contribution to journalArticle

Abstract

Recent PET imaging of glioblastoma multiforme and other high-grade gliomas using prostate-specific membrane antigen (PSMA)-targeted small-molecule radiotracers suggests a role for these agents in diagnostic imaging of recurrent/residual tumor and that PSMA-targeted endoradiotherapies may provide a new approach to therapy for patients with these difficult-to-treat tumors. We present a case of cerebral radionecrosis demonstrating PSMA-targeted radiotracer uptake. Our findings may represent a potential pitfall and limitation to the diagnostic application of PSMA-targeted agents for high-grade gliomas.

Original languageEnglish (US)
Pages (from-to)e419-e421
JournalClinical Nuclear Medicine
Volume43
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Diagnostic Imaging
Glioma
Residual Neoplasm
Glioblastoma
human glutamate carboxypeptidase II
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{972ac1e9561d4594a09083b594a7e284,
title = "Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas",
abstract = "Recent PET imaging of glioblastoma multiforme and other high-grade gliomas using prostate-specific membrane antigen (PSMA)-targeted small-molecule radiotracers suggests a role for these agents in diagnostic imaging of recurrent/residual tumor and that PSMA-targeted endoradiotherapies may provide a new approach to therapy for patients with these difficult-to-treat tumors. We present a case of cerebral radionecrosis demonstrating PSMA-targeted radiotracer uptake. Our findings may represent a potential pitfall and limitation to the diagnostic application of PSMA-targeted agents for high-grade gliomas.",
author = "{Salas Fragomeni}, {Roberto A.} and Kenneth Pienta and Pomper, {Martin Gilbert} and Michael Gorin and Steven Rowe",
year = "2018",
month = "11",
day = "1",
doi = "10.1097/RLU.0000000000002280",
language = "English (US)",
volume = "43",
pages = "e419--e421",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis

T2 - Implications for Diagnostic Imaging of High-Grade Gliomas

AU - Salas Fragomeni, Roberto A.

AU - Pienta, Kenneth

AU - Pomper, Martin Gilbert

AU - Gorin, Michael

AU - Rowe, Steven

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Recent PET imaging of glioblastoma multiforme and other high-grade gliomas using prostate-specific membrane antigen (PSMA)-targeted small-molecule radiotracers suggests a role for these agents in diagnostic imaging of recurrent/residual tumor and that PSMA-targeted endoradiotherapies may provide a new approach to therapy for patients with these difficult-to-treat tumors. We present a case of cerebral radionecrosis demonstrating PSMA-targeted radiotracer uptake. Our findings may represent a potential pitfall and limitation to the diagnostic application of PSMA-targeted agents for high-grade gliomas.

AB - Recent PET imaging of glioblastoma multiforme and other high-grade gliomas using prostate-specific membrane antigen (PSMA)-targeted small-molecule radiotracers suggests a role for these agents in diagnostic imaging of recurrent/residual tumor and that PSMA-targeted endoradiotherapies may provide a new approach to therapy for patients with these difficult-to-treat tumors. We present a case of cerebral radionecrosis demonstrating PSMA-targeted radiotracer uptake. Our findings may represent a potential pitfall and limitation to the diagnostic application of PSMA-targeted agents for high-grade gliomas.

UR - http://www.scopus.com/inward/record.url?scp=85054425282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054425282&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000002280

DO - 10.1097/RLU.0000000000002280

M3 - Article

VL - 43

SP - e419-e421

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 11

ER -